SLC5A2 and atherosclerosis: Many drugs, such as dipeptidyl peptidase 4 (DPP4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonists, and sodium glucose cotransporter 2 (SGLT-2) inhibitors (SGLT-2i), also inhibit atherosclerosis development by reducing the proinflammatory response in EAT and PVAT.